On April 19, 2018, a panel of outside experts convened by the FDA is scheduled to review GW Pharmaceuticals plc.’s (GWPH) NDA for Epidiolex, proposed for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.Epidiolex is the Company’s proprietary oral solution of pure plant-derived cannabidiol, or CBD.The FDA’s final decision on Epidiolex is expected by June 27, 2018.If approved, analysts expect Epidiolex to bring in excess of $1 billion in annual peak sales.GWPH closed Tuesday’s (Mar.27) trading at $110.27, down 4.14%.